Passage Bio (PASG)

• Market cap: $21.8M
• 1 day: -2.15%
• 5 days: -14.63%
• 1 month: -29.99%
• 3 months: -41.27%
• 6 months: -40.78%
• Year to date: -57.83%
• 1 year: -69.30%
• 5 years: -98.19%
• 10 years: -98.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Employees: 60

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

2% more funds holding

Funds holding: 45 [Q3] → 46 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

1.68% less ownership

Funds ownership: 62.6% [Q3] → 60.92% (-1.68%) [Q4]

20% less capital invested

Capital invested by funds: $27.1M [Q3] → $21.6M (-$5.49M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6 1,614% upside
• Avg. target: $6 1,614% upside
• High target: $6 1,614% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Geulah Livshits 7% 1-year accuracy 4 / 59 met price target

1,614% upside $6

Buy Maintained

4 Mar 2025